



CURRICULUM VITAE DEL PROF. DINO VAIRA

Prof. Dino Vaira - Foggia, 07/12/1955

FORMAZIONE

- 1974 Diploma di **Maturità classica**, Liceo "G.T. Giordani" di Monte S. Angelo (Foggia).
- 1980 **Laurea in Medicina e Chirurgia**, presso l'Università di Bologna, discutendo la tesi Sperimentale: "La terapia dell'ulcera duodenale: effetti a breve e lungo termine con Tritiozina" con il punteggio di 110/110
- 1980 **Abilitazione Professionale**
- 1984 **Diploma di Specialista in Malattie dell'Apparato Digerente** presso l'Università di Chieti con il punteggio di 70/70 e lode, discutendo la tesi sperimentale su: "Ipofunzione splenica nella malattia celiaca. Effetti della dieta agglutinata".
- 1986-90 Frequenza con l'incarico di **Middlegrade Registrar** (aiuto a tempo pieno di Gastroenterologia in Ospedale cronicizzato), presso il Dipartimento di Gastroenterologia del Middlesex Hospital, Londra, diretto dal Dr. PR Salmon e dal Dr A Hathfield.
Inizia la collaborazione scientifica con il Dr. Barry Marshall sul ruolo dell'Helicobacter pylori nelle malattie gastroduodenali.
- 1989 **Diploma di Specialità in Medicina Interna** presso l'Università di Bologna con il punteggio di 70/70 e lode, discutendo la tesi sperimentale su: "Il ruolo del Campylobacter pylori nella malattia peptica. Fatti e fantasie".
- 1990 **Tecnico laureato** presso l'Istituto di Clinica Medica I diretta dal Prof. Luigi Barbara
- 2000 **Professore Associato** in Medicina Interna presso l'Università di Bologna

ESPERIENZE

- 1977-79 Frequenza, con l'incarico di **Allievo interno**, l'Istituto di Patologia Speciale Medica e Metodologia Clinica diretta dal Prof. Giovanni Gasbarrini.
- 1979-80 segue il Prof. Giovanni Gasbarrini che ha assunto la titolarità della Patologia Medica III e Metodologia Clinica presso l'Università di Bologna e frequenta, in qualità di **Allievo interno**, l'Istituto di Patologia Speciale Medica e Metodologia Clinica diretta dal Prof. Giovanni Gasbarrini.
- 1980-81 Frequenza con l'incarico di **Medico interno**, presso l'Istituto di Clinica Medica I diretta dal Prof. Giuseppe Labò.
- 1981 **Tirocinio pratico Ospedaliero** presso la Patologia Speciale Medica I del Policlinico S. Orsola di Bologna.
- 1982-84 Frequenza con l'incarico di **Laureato frequentatore** presso l'Istituto di Clinica

- 1985-86 Medica I diretta dal Prof. Giuseppe Labò.
Frequenza presso la Divisione di Gastroenterologia dell'Ospedale M. Malpighi Policlinico S. Orsola-Malpighi, Bologna), diretta dal Prof. L. Gandolfi
- 1986-90 Frequenza con l'incarico di **Middlegrade Registrar** (aiuto a tempo pieno di Gastroenterologia in Ospedale clinicizzato), presso il Dipartimento di Gastroenterologia del Middlesex Hospital, Londra, diretto dal Dr. PR Salmon e dal Dr. A Hathfield.
- Inizia la collaborazione scientifica con il Dr. Barry Marshall sul ruolo dell'Helicobacter pylori nelle malattie gastroduodenali.**
- dal 1993 Esercita **funzioni assistenziali** nelle sale di degenza della Clinica Medica I diretta dal Prof. Luigi Barbara e successivamente dal Prof. Mario Miglioli.
- dal 1991 E'**responsabile del Servizio di Endoscopia Digestiva** presso l'Istituto di Clinica Medica I diretta dal Prof. Luigi Barbara e successivamente dal Prof. Mario Miglioli
- dal 1993 E'**responsabile** delle sale di degenza della Divisione di Medicina Interna diretta dal Prof. Mario Miglioli.

INSEGNAMENTI ACCADEMICI

- 1981-84 **insegnamento** nelle **esercitazioni teorico-pratiche** a studenti della facoltà di Medicina e Chirurgia presso l'Università degli Studi di Bologna (Istituto di Patologia Medica III e Metodologia Clinica negli anni accademici 1981-84).
- 1982-83 **insegnamento** di Patologia Medica ed Igiene nella Scuola per Infermieri Professionali di Foggia.
- 1986-90 insegnamento agli studenti del Corso di Laurea in Medicina e Chirurgia dell'Università di Londra presso il Policlinico Universitario "The Middlesex Hospital" di Londra.
- 1986-90 insegnamento agli specializzandi di Gastroenterologia afferenti al Policlinico Universitario del Middlesex Hospital dell'Università di Londra.
- dal 1991 E' **membro delle Commissioni d'esame** di Clinica Medica Generale e Terapia Medica.
- dal 2000 E' **membro delle Commissioni d'esame** di Medicina Interna.
- dal 2000-03 E' **docente di** Medicina Interna nell'insegnamento del Prof. R. Corinaldesi per gli studenti del V anno del corso di Laurea in Medicina e Chirurgia.
- dal 2004 in poi, E' **docente di** Oncologia Clinica nell'insegnamento del Prof. G. Biasco per gli studenti del IV anno del corso di Laurea in Medicina e Chirurgia.
- dal 2004 E' **membro delle Commissioni d'esame** di Oncologia Clinica.
- dal 2004 in poi, E' **docente nella Scuola di Specializzazione in Medicina Interna** nell'insegnamento per gli specializzandi del I anno del corso della suddetta Scuola di Specializzazione.
- dal 12/04 E' **vice-presidente** del corso di Laurea in Medicina e Chirurgia.
- dal 2000 Ha seguito come **relatore di tesi di Laurea Sperimentali** 11 laureandi del corso di Laurea in Medicina e Chirurgia.
- dal 2004 E' membro della Commissione Didattica del corso di Laurea in Medicina e Chirurgia.

PREMI

- 1981 vincitore di una **Borsa di Studio** per la partecipazione al "III Simposio Internazionale di Gastroenterologia" tenutosi a Bolzano
- 1982 vincitore di **Borsa di Studio** per la partecipazione al Congresso SIMAD 2 tenutosi a Genova
- 1983 vincitore di **Borsa di Studio** per la partecipazione al Congresso SIMAD 3 tenutosi a Bari
- 1984 vincitore di una **Borsa di Studio** istituita dalla RORER Italiana per "Attività di ricerca clinica" in Bologna.
- 1985 vincitore di **Borsa di Studio** al Congresso SIGE tenutosi a Milano.
- 1988 vincitore della **Borsa di Studio** SIED Emilia Romagna e SKF in Bologna nel Giugno 1988.

AFFILIAZIONI A SOCIETA' SCIENTIFICHE

- dal 1981 **socio ordinario** della Società Italiana di Gastroenterologia.
- dal 1989 socio ordinario della Società Inglese di Gastroenterologia (**BSG**).

- dal 2000 socio ordinario della Società Americana di Gastroenterologia (**AGA**)
- dal 2001 socio ordinario della Società Americana Endoscopia Gastrointestinale (**ASGE**).
- dal 2001 socio ordinario della Società Italiana di Medicina Interna (**SIMI**).

MEMBRO DI COMITATI EDITORIALI

- The American Journal of Gastroenterology
- Alimentary Pharmacology & Therapeutics
- Digestive Disease and Sciences
- Helicobacter
- THE LANCET (Edizione Italiana)
- Digestive and Liver Disease
- World Journal of Gastroenterology

REFEREE

- Lancet (Londra)
- Gastroenterology (Boston)
- Gut (Londra)
- Alimentary Pharmacology & Therapeutics
- American Journal Gastroenterology (Omaha, Nebraska)
- Journal of Clinical Pathology (Londra)
- Helicobacter
- Digestive Disease and Sciences (Pittsburgh, Stati Uniti)
- European Journal of Gastroenterology and Hepatology (Londra)
- Digestive and Liver Diseases (Roma)
- Argomenti di Gastroenterologia Clinica (Milano).

PARTECIPAZIONI A CONGRESSI

Membro di “Faculties” o relatore in più di 100 congressi internazionali e nazionali

PUBBLICAZIONI

- 215 pubblicazioni scientifiche internazionali in extenso
- 13 monografie internazionali
- 297 abstract o atti di congressi
- 124 pubblicazioni scientifiche nazionali
- 17 monografie nazionali

IMPACT FACTOR

L'impact facto totale delle pubblicazioni, in base allo Science Citaton Index del 2008, è 1279.

BREVETTI

Contitolare di due brevetti internazionali:

1. TEST ALL' UREASI (1989 Londra)
2. Method for determining Helicobacter pylori chemo sensitivity: PCT/IT 2007/000270

LINGUE

- italiano: madrelingua
- inglese: fluente parlato e scritto

COMITATI SCIENTIFICI DI ORGANIZZAZIONE

- Advanced ERCP course "The Middlesex Hospital" University of London, 1987.
- Advanced ERCP course "The Middlesex Hospital" University of London, 1988.
- Advanced ERCP course "The Middlesex Hospital" University of London, 1989.
- Interdisciplinary Course in Gastroenterology "Helicobacter Pylori Infection": Geneva 1993.
- Educational Training Workshop in Helicobacter Pylori: Bologna 1994.

Il dr. Barry Marshall viene per la prima volta in Italia e si instaura una profitta collaborazione Scientifica sull'utilizzo dell'urea breath test al carbonio 14.

- II Educational Training Workshop in Helicobacter Pylori: Bologna 1995.
- III Educational Training Workshop in Helicobacter Pylori: Bologna 1996.
- IV Educational Training Workshop in Helicobacter Pylori: Bologna 1997.
- V Educational Training Workshop in Helicobacter Pylori: Bologna 1998
- VI Educational Training Workshop in Helicobacter Pylori: Bologna 1999
- VII Educational Training Workshop in Helicobacter Pylori: Bologna 2000
- VIII Educational Training Workshop in Upper and Lower GI Diseases: Bologna 2001
- IX Educational Training Workshop in Digestive Diseases: Bologna 2002
- X Educational Training Workshop in Digestive and Liver Diseases: Bologna 2003
- XI Educational Training Workshop in Digestive and Liver Diseases: Bologna 2004

IL 10 DICEMBRE 2005 AI DR. BARRY MARSHALL E AL DR. ROBIN WARREN è stato CONSEGNATO IL PREMIO NOBEL PER LA SCOPERTA DEL RUOLO DELL'HELICOBACTER NELL'ULCERA PEPTICA.

PUBBLICAZIONI SCIENTIFICHE INTERNAZIONALI

1. Corazza G R, Risoni M, Milletti S, **Vaira D**, Gasbarrini G.
Mechanism of thrombocytosis in Whipple's disease.
Gastroenterology 1982; 82: 165 (letter) (**I.F. 12.9**).

1983

2. Corazza G R, Frisoni M, **Vaira D**, Gasbarrini G.
Effect of gluten-free diet on splenic hypo function of adult celiac disease.
Gut 1983; 24: 228-230 (**I.F. 9.3**).
3. Corazza G R, Frisoni M, **Vaira D**, Gasbarrini G.
Splenic function in adult celiac disease.
Gut 1983; 82: 964-965 (letter) (**I.F. 9.3**).
4. Corazza G R, **Vaira D**, Milletti S, Vanzini S, Gasbarrini G.
Controlled clinical evaluation of Pinaverium Bromide and Trimebutine in functional disorders of the colon.
Acta Terapeutica 1983; 9: 383-389. (**I.F. 0.7**).

1984

5. Corazza G R, Tarozzi C, **Vaira D**, Frisoni M, Gasbarrini G.
Return of splenic function after splenectomy: how much tissue is needed?
British Medical Journal 1984; 289: 861-864 (**I.F. 13.7**).
6. Corazza G R, Frisoni M, **Vaira D**, Gasbarrini G.
Fatal pneumonia in a patient with celiac disease and splenic atrophy.
The Italian Journal of Gastroenterology 1984; 16: 300-301 (**I.F. 2.9**).
7. Gasbarrini G, Corazza G R, **Vaira D**, Frazzoni M, Strocchi A, Prati C, Feliciani M, Frisoni M.
Critical evaluation of malabsorption test.
Problems and controversies in Gastroenterology 1984; 123-130.

1986

8. Gandolfi L, Rossi A, **Vaira D**, Tonti R, Ramini R.
Endoscopic retrograde cholangiopancreatography (ERCP) in the elderly.
Acta Gastro-Enterologica Belgica 1986; II 602-607. (**I.F. 1**).

1988

9. **Vaira D**, Holton J, Londei M, Beltrandi E, Salmon P. R, D'Anastasio C, Dowsett J, Bertoni F, Grauenfels P, Gandolfi L.
Campylobacter pylori in abattoir workers: is it a zoonosis?
The Lancet: 1988; ii 725-726 (**I.F. 30.8**).
10. **Vaira D**, D'Anastasio C, Holton J, Dowsett J, Londei M, Salmon P R, Gandolfi L.
Is Campylobacter pylori a zoonosis?
The Lancet 1988; ii: 1149 (letter) (**I.F. 30.8**).
11. **Vaira D**, Holton J, Cairns S. R., Falzon M, Polydorou A, Dowsett J, Salmon P R.
Antibody titres to Campylobacter pylori after treatment for gastritis.
British Medical Journal 1988: 297: 397 (**I.F. 13.7**).
12. Gandolfi L, **Vaira D**, Bertoni F, Rossi A, Solmi L, Leo P, Muratori R.
Cancer of gastric stump in Italy, 1979-1986.
Gastrointestinal Endoscopy 1988; 34: 242-246 (**I.F. 6.7**).
13. Dowsett J, **Vaira D**, Polydorou A, Russel R C G, Salmon P R.
Interventional endoscopy in the pancreaticobiliary tree
The American Journal of Gastroenterology 1988: 83: 1328-1336 (**I.F. 6**).
14. **Vaira D**, Holton J, Falzon M, Cairns S, Dowsett J, Polydorou A, Salmon P R.
Investigation of Campylobacter pylori associated gastritis by histology, culture, urease test, brushings and antibody levels.
The Italian Journal of Gastroenterology 1988: 20: 299-304 (**I.F. 2.9**).
15. **Vaira D**, Holton J Cairns S, Polydorou A, Falzon M, Dowsett J, Salmon P R.
Urease test for Campylobacter pylori: care in interpretation.
Journal of Clinical Pathology 1988; 41: 812-13. (**I.F. 2.3**).
16. **Vaira D**, Holton J, Cairns S, Falzon M, Salmon P R.
Four hour rapid urease test (RUT) for detecting Campylobacter pylori: is it reliable enough to start treatment?
Journal of Clinical Pathology 1988; 41: 355-356 (letter) (**I.F. 2.3**).
17. Dowsett J, Miller R, Davidson R, **Vaira D**, Polydorou A, Cairns S R, Weller I V D.
Sclerosing Cholangitis in Acquired Immunodeficiency Syndrome.
Scandinavian Journal of Gastroenterology 1988; 23: 1267-1274 (**I.F. 2**).

1989

18. **Vaira D**, D'Anna L, Ainley C, Dowsett J, Williams S, Baillie J, Cairns S, Croker J, Salmon P, Cotton P, Russell C, Hatfield A.
Endoscopic sphincterotomy in 1000 consecutive patients.
Lancet 1989; ii: 431-434 (**I.F. 30.8**).
19. Oderda G, **Vaira D**, Holton J, Ainley C, Altare F, Ansaldi N.
Amoxicillin plus tinidazole for Campylobacter pylori gastritis in children: assessment by serum IgG antibody, pepsinogen I, and gastrin levels.
Lancet 1989; i: 690-692. (**I.F. 30.8**).
20. Smith T, **Vaira D**, Ailey C, Holton J.
Campylobacter pylori, gastrin and duodenal ulcer.
Lancet 1989; ii: 431-434 (letter) (**I.F. 30.8**).
21. **Vaira D**, Holton J, Osborn J, Dowsett J, McNeil I, Hatfield A.
Use of endoscopy in patients with dyspepsia
British Medical Journal 1989; 299: 237 (**I.F. 13.7**).
22. **Vaira D**, Holton J, McNeil N I.
Use of endoscopy in patients with dyspepsia
British Medical Journal 1989; 299: 621-622 (letter) (**I.F. 13.7**).

23. Dowsett J, **Vaira D**, Hatfield A R W, Cairns S R, Polydorou A, Frost R, Croker J, Cotton P B, Russell R C G, Mason R R.
Endoscopic biliary therapy using the combined percutaneous and endoscopic technique.
Gastroenterology 1989; 96: 1180-6. (**I.F. 12.9**).
24. **Vaira D**, Holton J.
Serum immunoglobulin G antibody levels for *Campylobacter pylori* diagnosis.
Gastroenterology 1989; 97: 1069-1070 (letter) (**I.F. 12.9**).
25. **Vaira D**, Dowsett J, Hatfield A R W, Cairns S R, Polydorou A, Cotton P B, Salmon P R, Russell R C G.
Is duodenal diverticulum a risk factor for sphincterotomy?
Gut 1989; 30: 939-942 (**I.F. 9.3**).
26. Oderda G, **Vaira D**, Holton J, Dowsett J, Ansaldi N.
Serum pepsinogen I and IgG antibody to *Campylobacter pylori* in non-specific abdominal pain in childhood.
Gut 1989; 30:912-916. (**I.F. 9.3**).
27. **Vaira D**, Oderda G, Holton J, Smith A, Ainley C.
14C-Urea Test for *C. pylori*.
Gut 1989; 30:1657 (letter) (**I.F. 9.3**).
28. **Vaira D**, Holton J.
Urease test for *Campylobacter pylori* detection.
The American Journal of Gastroenterology 1989; 84: 836-837 (letter) (**I.F. 6**).
29. Polydorou A, Dowsett J, **Vaira D**, Salmon P R, Cotton P B, Russell R C G.
Endoscopic therapy of the sump syndrome.
Endoscopy 1989; 21, 126-130. (**I.F. 5.4**).
30. **Vaira D**, Holton J, Ainley C, Salmon P.
Campylobacter pylori and gastritis.
Current Opinion in Gastroenterology 1989; 5: 817-823 (**I.F. 4.3**).
31. Dowsett J, Cairns S R, **Vaira D**, Polydorou A, Hatfield A R W, Russell R C G.
Endoscopic endoprothesis insertion following failure of cholecystojejunostomy in pancreatic carcinoma.
British Journal of Surgery 1989; 76: 454-456 (**I.F. 4.1**).
32. **Vaira D**, Holton J, Salmon P R.
How specific is the rapid urease test for diagnosing *Campylobacter pylori*?
Journal of Clinical Pathology 1989; 42: 671 (letter) (**I.F. 2.3**).
33. **Vaira D**, Holton J, Ainley C, Londei M, Romanos A, Maldini M, Gandolfi L.
The source of *Campylobacter pylori*.
Biomed and Pharmacotherapeutics 1989; 43: 447-450 (**I.F. 2.1**).

1990

34. Bedwell J, Holton J, **Vaira D**, Mac Robert A, Bown S.
In vitro killing of *Helicobacter pylori* with photodynamic therapy.
Lancet 1990; i: 1287 (letter) (**I.F. 30.8**).
35. Corazza G R, Menozzi M, Strocchi A, Rasciti R, **Vaira D**, Lecchini R, Avanzini P, Chezzi C, Gasbarrini G.
The diagnosis of small bacterial overgrowth.
Gastroenterology 1990; 98: 302-309 (**I.F. 12.9**).
36. Dowsett J, Polydorou A, **Vaira D**, D'Anna L, Ashraf M, Croker J, Salmon P, Russell R, Hatfield A.
Needle knife papillotomy: how safe and how effective?
Gut 1990; 31: 905-908 (**I.F. 9.3**).
37. **Vaira D**, Holton J, Osborn J, D'Anna L, Romanos A, Falzon M, McNeil N I.
Endoscopy in dyspeptic patients: Is gastric mucosal biopsy useful?
The American Journal of Gastroenterology 1990; 85:701-704 (**I.F. 6**).
38. **Vaira D**, Holton J, Ainley C, Barbara L.
Helicobacter pylori and acid-related diseases of the stomach: mechanisms of pathogenesis.
Current Opinion in Gastroenterology 1990; 6: 882-887 (**I.F. 4.3**).

39. Oderda G, **Vaira D**, Dell'Olio D, Holton J, Forni M, Altare F, Ansaldi N.
Serum pepsinogen I and gastrin concentrations in children positive for Helicobacter pylori.
Journal of Clinical Pathology 1990; 43: 762-765 (**I.F. 2.3**).
40. **Vaira D**, Holton J, Dowsett J, Oderda G, Barbara L.
Helicobacter pylori: its role in gastric disease.
Digestive Disease 1990; 8:322-336 (**I.F. 1.5**).
41. **Vaira D**, Holton J, Oderda G, Taylor D, Colecchia A, Gandolfi L.
Transmission and source of Helicobacter pylori in Menge H, Gregor M, Tytgat G,
Marshall B, McNulty C.
Helicobacter pylori: epidemiology and diagnosis.
Insights into Helicobacter pylori and peptic disorders 1990; 11: 104-109.

1991

42. **Vaira D**, Miglioli M, Holton J, Mulè P, Barbara L.
Screening for Helicobacter pylori.
Lancet 1991, ii: 1149 (letter) (**I.F. 30.8**).
43. Nussinson E, Cairns S, **Vaira D**, Dowsett J, Mason R.
A 10 year single centre experience of percutaneous and endoscopic extraction of bile duct
stones with T tube in situ.
Gut 1991; 32: 1040-1043 (**I.F. 9.3**).
44. **Vaira D**, Holton J.
Is gastric mucosal biopsy useful?
The American Journal of Gastroenterology 1991; 96: 647-48 (letter) (**I.F. 6**).
45. **Vaira D**, Holton J, Miglioli M, Barbara L.
Pathogenic mechanism of acid-related diseases: Helicobacter and other spiral organisms.
Current Opinion in Gastroenterology 1991; 7: 881-887 (**I.F. 4.3**).
46. **Vaira D**, Modugno V, Miglioli M, Holton J, Vergura M, Marchesini F, Scagliusi V,
Barbara L.
Prevalence of Helicobacter pylori in military barracks.
The Italian Journal of Gastroenterology 1991; 25: 215 (**I.F. 2.9**).
47. Oderda G, **Vaira D**, Holton J, Ainley C, Altare F, Boero M, Smith A, Ansaldi N.
Helicobacter pylori in children with peptic ulcer and their families.
Digestive Diseases and Sciences 1991; 36: 572-576 (**I.F. 1.5**).
48. Oderda G, **Vaira D**.
Infection à Helicobacter pylori dans l'enfance.
Acta Endoscopica 1991; 21: 43-47 (**I.F. 0.07**).
49. **Vaira D**, Holton J, Barbara L.
Helicobacter pylori and Gastroduodenal diseases.
Gastroenterology International 1991; 4: 70-76.

1992

50. Oderda G, **Vaira D**, Holton J.
Age-related increase of Helicobacter pylori frequency in symptom-free and dyspeptic
children.
Lancet 1992; ii: 671-672 (letter) (**I.F. 30.8**).
51. Oderda G, **Vaira D**, Ainley C, Holton J, Osborn J, Altare F, Ansaldi N.
Eighteen month follow up of Helicobacter pylori positive treated with amoxicillin and
tinidazole.
Gut 1992; 33: 1328-30 (**I.F. 9.3**).
52. **Vaira D**, Holton J, Miglioli M, Mulè P, Menegatti M, Barbara L.
Helicobacter pylori and other spiral organisms.
Current Opinion in Gastroenterology, 1992; 8: 918-926 (**I.F. 4.3**).
53. **Vaira D**, Ferron P, Negrini R, Cavazzini L, Holton J, Ainley C, Londei M, Vergura M, Dei
R, Colecchia A, Taylor D, Pieracci F, Nenci I, Gandolfi L, Barbara L.
Detection of Helicobacter pylori-like organisms in the stomach of some food-source animals

- using a monoclonal antibody.
The Italian Journal of Gastroenterology 1992; 24:181-184 (**I.F. 2.9**).
54. **Vaira D**, Holton J, Ainley C, Falzon M, Osborn J, D'Anna L, Romanos A, Chandrakumaran K, McNeil N I.
Double blind trial of colloidal bismuth subcitrate versus placebo in Helicobacter pylori positive patients with non-ulcer dyspepsia.
The Italian Journal of Gastroenterology 1992; 24: 400-404 (**I.F. 2.9**).
55. Croker JR, Williams SG, Charlton M, **Vaira D**, Dowsett J.
Endoscopic therapy for bile duct stones in a geriatric population.
Postgraduate Medical Journal 1992; 68: 457-60 (**I.F. 1.3**).
56. Ahmed A, Holton J, **Vaira D**, Smith SK, Hoult JRS.
Eicosanoids synthesis and Helicobacter pylori associated gastritis: increase in leukotriene C4 generation associated with H. pylori colonisation.
Prostaglandins 1992; 44: 75-86.

1993

57. **Vaira D**, Menegatti M, Miglioli M, Barbara L.
Source of Helicobacter pylori infection.
The American Journal of Gastroenterology 1993; 88: 1297 (letter) (**I.F. 6**).
58. **Vaira D**, Corbelli C, Brunetti G, Menegatti M, Levorato M, Mulè P, Colombo P, Miglioli M, Barbara L.
Gastric retention of sucralfate gel and suspension in upper gastrointestinal disease.
Alimentary Pharmacology & Therapeutic 1993; 7: 531-535 (**I.F. 4.3**).
59. Biasco G, Paganelli GM, **Vaira D**, Holton J, Di Febo G, Brillanti S, Miglioli M.
Serum pepsinogen I and II concentrations and IgG antibody to Helicobacter pylori in dyspeptic patients.
Journal of Clinical Pathology 1993; 46: 826-828 (**I.F. 2.3**).
60. **Vaira D**, Miglioli M, Menegatti M, Mulè P, Barbara L.
Treatment of symptom-free Helicobacter pylori-positive subjects.
European Journal of Gastroenterology & Hepatology 1993; 5: 96-98 (**I.F. 1.6**).
61. Mulè P, **Vaira D**, Menegatti M, Boschi S, Miglioli M, Barbara L.
Clinical aspects of serology in the diagnosis of Helicobacter pylori infection.
European Journal of Gastroenterology & Hepatology 1993; 5: 54-56 (**I.F. 1.6**).
62. Menegatti M, **Vaira D**, Mulè P, Miglioli M, Barbara L.
Comparison of urease tests for the diagnosis of Helicobacter pylori infection.
European Journal of Gastroenterology & Hepatology 1993; 5: 38-40 (**I.F. 1.6**).
63. **Vaira D**, Cairns S, Miglioli M, Mulè P, Menegatti M, Barbara L.
Biliary surgery without the surgeon.
Digestive Diseases 1993; 11: 278-87 (**I.F. 1.5**).

1994

64. **Vaira D**, Miglioli M, Mulè P, Holton J, Menegatti M, Vergura M, Biasco G, Conte R, Logan R, Barbara L.
Prevalence of peptic ulcer in Helicobacter pylori positive blood donors.
Gut 1994; 35: 309-312 (**I.F. 9.3**).
65. Chandrakumaran K, **Vaira D**, Hobsley M.
Duodenal ulcer, Helicobacter pylori, and gastric secretion.
Gut 1994; 35: 1033-1036 (**I.F. 9.3**).
66. Gionchetti P, **Vaira D**, Campieri M, Holton J, Menegatti M, Belluzzi A, Bertinelli E, Ferretti M, Brignola C, Miglioli M, Barbara L.
Enhanced mucosal interleukin 6 and 8 in Helicobacter pylori positive dyspeptic patients.
The American Journal of Gastroenterology 1994; 89: 883-887 (**I.F. 6**).
67. **Vaira D**, Holton J, Miglioli M, Menegatti M, Mulè P, Barbara L.
Peptic ulcer disease and Helicobacter pylori infection.
Current Opinion in Gastroenterology 1994; 10: 98-104 (**I.F. 4.3**).

68. Oderda G, **Vaira D**, Holton J.
Seroconversion of Helicobacter pylori.
Journal of Clinical Pathology 1993; 47: 286 (letter) (**I.F. 2.3**).
69. **Vaira D**, Menegatti M, Miglioli M, Mosconi G, Mulè P, Barbara L.
Tetracycline for Helicobacter pylori.
Annals of Experimental and Clin Med 1994; 2: 90-94.

1995

70. Menegatti M, **Vaira D**, Miglioli M, Vergura M, Holton J, Petronelli A, Biasco G, Gusmaroli R, Milesi F, Ricci C, Azzarone P, Maiolo P, Casadei A, Mulè P, Rodi M, Giorcelli W, Zambelli A, Lupinacci G, Pannuti F, Barbara L.
Helicobacter pylori in patients with gastric and non gastric cancer.
The American Journal of Gastroenterology 1995; 90: 1278-1281 (**I.F. 6.4**).
71. Holton J, **Vaira D**, Menegatti M, Barbara L.
The susceptibility of Helicobacter pylori to the rifamycin, Rifaximin.
Journal of Antimicrobial Chemotherapy 1995; 35: 545-549 (**I.F. 4.3**).
72. Biselli R, **Vaira D**, Miglioli M, Menegatti M, Nisini R, Barbara L, D'Amelio R.
Spectroscopic analysis of antibodies to Helicobacter pylori in patients with antral gastritis and duodenal ulcer.
Journal of Clinical Pathology 1995; 48:1117-21. (**I.F. 2.3**).
73. **Vaira D**, Miglioli M, Menegatti M, Holton J, Boschini A, Vergura M, Ricci C, Azzarone P, Mulè P, Barbara L, Ainley C.
Helicobacter pylori status, endoscopic findings, and serology in HIV-1-positive patients.
Digestive Disease and Sciences 1995; 40: 1622-1626. (**I.F. 1.8**).

1996

74. **Vaira D**, Stanghellini V, Menegatti M, Miglioli M, Corinaldesi R & The Italian Helicobacter Study Group.
IgG ELISA antibodies and detection of Helicobacter pylori in elderly patients.
Lancet 1996; i: 269-270 (letter) (**I.F. 30.8**).
75. Negrini R, Savio A, Poiesi C, Appelmek BJ, Buffoli F, Paterlini A, Cesari P, Graffeo M, **Vaira D**, Franzin G.
Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis.
Gastroenterology 1996;111:655-65. (**I.F. 12.9**).
76. Biasco G, Paganelli GM, Terranova A, Santucci R, Renga M, **Vaira D**, Amorosi A, Pileri S.
Observer variation in histological assessment of Helicobacter pylori on gastric biopsies.
The American Journal of Gastroenterology 1996; 91: 1282 (letter) (**I.F. 6**).
77. Miglioli M, Bianchi Porro G, **Vaira D**, Menegatti M, Brunetti G, Petrillo M, Ardizzoni S, Frizziero L, Montrone F, Grandinetti G.
Prevention with sucralfate gel on NSAID-induced Gastroduodenal damage in arthritic patients.
The American Journal of Gastroenterology 1996; 91: 2367-71 (**I.F. 6**).
78. Menegatti M, **Vaira D**, Holton J, Miranda F, Ricci C, Gusmaroli R, Ainley C, Miglioli M, Barbara L.
Serological response to Helicobacter pylori in gastric and non gastric cancer.
Clinical Science 1996; 91:219-223. (**I.F. 3.9**).
79. **Vaira D**.
How to manage the dyspeptic patient.
Helicobacter 1996; 1: 261-62. (**I.F. 2.8**).

1997

80. **Vaira D**, Menegatti M, Miglioli M.
What is the role of Helicobacter pylori in complicated ulcer disease?
Gastroenterology 1997; 113: S78-84 (**I.F. 12.9**).
81. **Vaira D**, Stanghellini V, Menegatti M, Miglioli M, Corinaldesi R & The Italian Helicobacter Pylori Study Group.
Prospective screening of dyspeptic patients by Helicobacter pylori serology: a worldwide safe policy?
Endoscopy 1997; 29: 595-601 (**I.F. 5.5**).
82. Palli D, **Vaira D**, Menegatti M, Saieva C & Italian Helicobacter Pylori Study Group
A serologic survey of Helicobacter pylori infection in 3281 patients endoscoped for upper gastrointestinal symptoms through Italy.
Alimentary Pharmacology & Therapeutics 1997; 11: 719-28 (**I.F. 4.3**)
83. **Vaira D**, Menegatti M, Landi F, Ricci C, Ali' A, Miglioli M & The Italian Helicobacter Pylori Study Group.
Usefulness of serology in pre endoscopic screening.
Helicobacter 1997; 2: S38-43. (**I.F. 2.8**).
84. Oderda G, Ponzetto A, Boero M, Bellis D, Forni M, **Vaira D**, Ansaldi N.
Family treatment of symptomatic children with Helicobacter pylori infection.
The Italian Journal of Gastroenterology 1997; 29: 509-14 (**I.F. 2.9**).
85. Siringo S, **Vaira D**, Menegatti M, Piscaglia F, Soccorsi S, Miglioli M, Corinaldesi R, Bolondi L
High prevalence of Helicobacter pylori in liver cirrhosis. Relationship with clinical and endoscopic features and the risk of peptic ulcer.
Digestive Disease and Sciences 1997; 42: 2024-30 (**I.F. 1.5**).
86. **Vaira D**, Menegatti M, Miglioli M, Ferrieri A, Holton J, Biasco G, Azzarone P, Ricci C, Gusmaroli R, Milesi F, Rodi M, Giorcelli W, Barbara L.
Rifaximin suspension for the eradication of Helicobacter pylori.
Current Therapeutic Research 1997; 58: 300-308 (**I.F. 0.47**).

1998

87. Figura N, Vindigni C, Covacci A, Presenti L, Burroni D, Vernillo R, Banducci T, Roviello F, Marrelli D, Biscontri M, Kristodhullu S, Gennari C, **Vaira D**.
CagA positive and negative Helicobacter pylori strains are simultaneously present in the stomach of most patients with non ulcer dyspepsia: relevance to histological damage.
Gut 1998; 42: 772-778 (**I.F. 9.3**).
88. **Vaira D**, Holton J, Menegatti M, Landi F, Ricci C, Ali' A, Gatta L, Farinelli S, Acciardi C, Massardi B, Miglioli M & The Italian Helicobacter Pylori Study Group.
Blood tests in management of Helicobacter pylori infection.
Gut 1998; 42: S39-S46 (**I.F. 9.3**).
89. Peitz U, Menegatti M, **Vaira D**, Malfertheiner P.
The European Meting on Helicobacter pylori. Therapeutic news from Lisbon.
Gut 1998; 42: S66-S69 (**I.F. 9.3**).
90. Neri M, Vaira D, Palli D, Menegatti M, Landi F, Saieva C, Ricci C, Miglioli M & The Italian Helicobacter Pylori Study Group.
Symptoms and Helicobacter pylori, any link?
The American Journal of Gastroenterology 1996; 93: 2633-34 (letter) (**I.F. 6**).
91. **Vaira D**, Ali' A, Gatta L, O'Morain C.
Treatment of Helicobacter pylori
Current Opinion in Gastroenterology 1998; 14: S71-S78 (**I.F. 4.3**).
92. **Vaira D**, Holton J.
H pylori and gastric physiology
Helicobacter 1998; 3: 2-3. (**I.F. 2.8**).
93. **Vaira D**, Menegatti M, Salardi S, Ali A, Stella FA, Figura N, Landi F, Holton J, Farinelli S, Cuccaro V, Miglioli M, Cacciari E.
Helicobacter pylori and diminished growth in children: is it simply a marker of deprivation?

- The Italian Journal of Gastroenterology 1998; 30: 129-33. (**I.F. 2.9**).
94. **Vaira D**, Menegatti M, Gatta L, Ricci C, Landi F, Alì A, Miglioli M, Holton J.
Routes of transmission of Helicobacter pylori infection.
The Italian Journal of Gastroenterology 1998; 30 (Suppl. 3): S 279-85(**I.F. 2.9**).
95. Ricci C, Gatta L, Miglioli M, **Vaira D**.
Therapeutic news on Helicobacter pylori from Budapest and Wien.
The Italian Journal of Gastroenterology 1998; 30: 129-33. (**I.F. 2.9**).
96. Figura N, Cetta F, Angelico M, Montalto G, Cetta D, Pacenti L, Vindigni C, **Vaira D**, Festuccia F, De Santis A, Rattan G, Giannace R, Campagna S, Gennari C.
Most Helicobacter pylori infected patients have specific antibodies, and some also have H. pylori antigens and genomic material in bile. Is it a risk factor for gallstone formation?
Digestive Disease and Sciences 1998; 43:854-862. (**I.F. 1.5**).
97. Menegatti M, **Vaira D**, Figura N, Holton J, Biasco G, Ricci C, Oderda G, Conte R, Miglioli M.
Clinical significance of Helicobacter pylori seropositivity and seronegativity in asymptomatic blood donors.
Digestive Disease and Sciences 1998; 43: 2542-48. (**I.F. 1.5**).
98. Holton J, Basset C, Youinou P, **Vaira D**.
Emerging therapeutic targets in the eradication of Helicobacter pylori.
Emerging Therapeutic Targets 1998; 2: 107-123.

1999

99. **Vaira D**, Malfertheiner P, Megraud F, Axon ATR, Deltenre M, Hirschl A, Gasbarrini G, O' Morain C, Pajares JG, Quina M, Tytgat GNJ& European Helicobacter pylori HPSA study Group.
Diagnosis of Helicobacter pylori infection using a novel, non-invasive antigen based assay in a European multicentre study.
Lancet 1999; 354: 30-33 (**I.F. 30.8**).
100. **Vaira D**, Malfertheiner P, Megraud F, Axon ATR, & European Helicobacter pylori HPSA Study Group.
Diagnosis of Helicobacter pylori infection by HpSA.
Lancet 1999; 354: 1732 (letter) (**I.F. 30.8**).
101. **Vaira D**, Holton J, Menegatti M, Ricci C, Landi F, Ali' A, Gatta L, Acciardi C, Farinelli S, Crosatti M, Berardi S, Miglioli M.
New immunological-based assays for the diagnosis of Helicobacter pylori infection.
Gut 1999, 45: I 23-27 (**I.F. 9.3**).
102. Ali' A, Menegatti M, Gatta L, Mucci F, Landi F, Holton J, Ricci C, Acciardi C, Miglioli M, **Vaira D**.
A second-line anti-helicobacter pylori therapy in patients with previously failed treatment.
The American Journal of Gastroenterology 1999; 94 (8): 2321-23 (letter) (**I.F. 6**).
103. van der Hulst RWM, Lamouliatte H, Megraud F, Pounder RE, Stolte M, **Vaira D**, Williams M, Tytgat GNJ. Laser assisted ratio analyser-¹³C-urea breath testing. A novel non-invasive system for the diagnosis of H pylori infection. A prospective comparative diagnostic multicentre study.
Alimentary Pharmacology & Therapeutics 1999; 13: 1171-1177 (**I.F. 4.3**).
104. Figura N, Perrone F, Gennari C, Orlandini G, Bianciardi L, Giannace R, Vagliansinti N, **Vaira D**, Rottoli P.
Food allergy and Helicobacter pylori infection.
The Italian Journal of Gastroenterology 1999; 31: 186-91. (**I.F. 2.9**).
105. Salardi S, Cacciari E, Menegatti M, Landi F, Mazzanti L, Stella FA, Pirazzoli P, **Vaira D**.
Helicobacter pylori and Type 1 Diabetes Mellitus in Children.
Journal of Paediatric Gastroenterology & Nutrition 1999; 28-307-309 (**I.F. 2.1**).
106. Dore MP, Bilotta M, **Vaira D**, Manca A, Massarelli G, Gioacchini L, Atzei A, Pisanu G, Graham DY, Realdi G.
High prevalence of Helicobacter pylori infection in shepherds.
Digestive Disease and Sciences 1999; 44: 1161-64 (**I.F. 1.5**).

107. Fusconi M, **Vaira D**, Menegatti M, Farinelli S, Figura N, Holton J, Ricci C, Corinaldesi R, Miglioli M.
Anti-cagA reactivity in Helicobacter pylori negative subjects: a comparison of three different methods.
Digestive Disease and Sciences 1999; 44: 1691-1695 (**I.F. 1.5**).
108. Figura N, Di Cairano G, Lorè F, Guarino E, Gragnoli A, Cataldo D, Giannace R, Vaira D, Bianciardi L, Kristodohullu S, Lenzi C, Torricelli V, Orlandini G, Gennari C.
The infection by Helicobacter pylori strains expressing CagA is highly prevalent in women with autoimmune thyroid disorders.
Journal of Physiology and Pharmacology 1999; 50: 817-26 (**I. F. 1.5**).
109. Cacciari E, Menegatti M, Salardi S, Ali' A, Stella FA, Figura N, Landi F, Holton J, Farinelli S, Cuccaro V, Miglioli M, **Vaira D**.
Helicobacter pylori infection and cytotoxic antigen associated gen "A" status in short children.
Journal of Paediatric Endocrinology & Metabolism 1999; 12-197-201 (**I.F.0.7**).

2000

110. Barnes I, Holton J, **Vaira D**, Spigelman M, Thomas MG
An assessment of the long-term preservation of the DNA of a bacterial pathogen in ethanol-preserved archival material.
Journal of Pathology 2000; 192: 554-9 (**I.F. 6.4**).
111. **Vaira D**, Malfertheiner P, Mégraud F, Axon ATR, Deltenre M, Gasbarrini G, O' Morain C, Pajares JG, Quina M, Tytgat GNJ& European Helicobacter pylori HPSA study Group.
Non invasive antigen based assay for assessing Helicobacter pylori eradication. A European multicentre study.
American Journal of Gastroenterology 2000; 95: 925-929. (**I.F. 6**)
112. Menegatti M, **Vaira D**, Figura N, Palli D, Miglioli M & The Italian Helicobacter pylori Study Group
Age, Helicobacter pylori and/or CagA antibodies as a pre-endoscopic screening policy.
American Journal of Gastroenterology 2000; 95: 320-21. (letter) (**I.F. 6**)
113. Checchi L, Felice P, Acciardi C, Ricci C, Gatta L, Polacci R, Holton J, **Vaira D**.
Absence of Helicobacter pylori in dental plaque assessed by stool test.
American Journal of Gastroenterology 2000, 95: 3005-6 (letter) (**I.F. 6**)
114. **Vaira D**, Holton J, Menegatti M, Ricci C, Gatta L, Geminiani A, Miglioli M.
Review article: invasive and non-invasive tests for Helicobacter pylori diagnosis.
Alimentary Pharmacology & Therapeutics 2000; 14: 13-22 (**I.F. 4.3**).
115. **Vaira D**, Ricci C, Perna F, Gatta L, Tampieri A, Miglioli M
Diagnosis of Helicobacter pylori infection: which is the best test? Stool test
Digestive Liver Diseases 2000; 32: S193-S195 (**I.F. 2.9**).
116. **Vaira D**, Menegatti M, Ricci C, Gatta L, Berardi S, Miglioli M
Accurate diagnosis of Helicobacter pylori: stool tests
Gastroenterology Clinics of North America. BJ Marshall E Sanders (**I.F. 2.5**).
117. Reinhard J, Basset C, Holton J, Binks M, Youinou P, **Vaira D**.
Image analysis method to assess adhesion of Helicobacter pylori to gastric epithelium using confocal Laser scanning microscopy
Journal of Microbiological Method 2000; 39; 179.187 (**I.F. 2.4**).
118. Menegatti M, Figura N, Farinelli S, Landi F, Acciardi C, Ricci C, Holton J, Gatta L, Crosatti M, Geminiani R, Polacci R, Miglioli M, **Vaira D**,
Helicobacter pylori seroconversion in asymptomatic blood donors. A five-years follow-up.
Digestive Disease and Sciences 2000; 45: 1653-59 (**I.F. 1.5**).
119. Savarino V, Landi F, Dulbecco P, Ricci C, Tesseri L, Biagini R, Miglioli M, Celle G, **Vaira D**.
Isotope Ratio mass-Spectrometry (IRMS) versus Laser-Assisted Ratio Analyser (LARA): a comparative study using two doses of 13C-urea and two test meals for pre- and post-treatment diagnosis of Helicobacter pylori infection.
Digestive Disease and Sciences 2000; 45: 2168: 74 (**I.F. 1.5**).

120. **Vaira D**, Ricci C, Menegatti M, Gatta L, Geminiani A, Miglioli M.
 Clinical Role of Fecal antigen determination in the diagnosis of Helicobacter pylori.
 Clinical Laboratory 2000; 46: 487-91. (**I.F. 1**)
121. **Vaira D**, Ricci C, Menegatti M, Acciardi C, Gatta L, Geminiani A, Miglioli M.
 Diagnosis of Helicobacter pylori infection: faecal antigen determination.
 Helicobacter pylori: Basic mechanisms to clinical cure 2000
 Edited by Hunt RH, Tytgat GNJ.pg 115-122.

2001

122. **Vaira D**, Vakil N.
 Blood, urine, stool, breath, mucus and Helicobacter pylori
 Gut 2001; 48: 287-89 (**I.F. 9.3**)
123. **D. Vaira**, C. Ricci, M. Menegatti, L. Gatta, S. Berardi, A. Tampieri, M. Miglioli
 Stool test for Helicobacter pylori.
 American Journal of Gastroenterology 2001; 96: 1935-37 (letter) (**I.F. 6**)
124. Manes G, Balzano A, Iaquinto G, Ricci C, Piccirillo M, Giardullo N, Todisco A, Lionello M,
Vaira D...
 Accuracy of the stool antigen test in the diagnosis of *Helicobacter pylori* infection
 in the pre-treatment assessment and in patients on omeprazole therapy
 Alimentary Pharmacology & Therapeutics 2001; 15: 73-79 (**I.F. 4.3**).
 125. **D Vaira**, J Holton, Chiara Ricci, M Menegatti, L Gatta, Sonia Berardi, A. Tampieri, M Miglioli
 Review article: the transmission of Helicobacter pylori from stomach to stomach.
 Alimentary Pharmacology & Therapeutics 2001; 15: 33-42 (**I.F. 4.3**).
 126. Fernando N, Holton J, Zulu I, **Vaira D**, Mwaba P, Kelly P.
 Helicobacter pylori infection in an urban African population.
 Journal of Clinical Microbiology 2001; 39: 1323-7 (**I.F.4.1**).
 127. Fernando N, Perera N, **Vaira D**, Holton J
 Helicobacter pylori in school children from the western province of Sri Lanka
 Helicobacter 2001; 6: 169-174 (**I.F. 2.8**).
 128. **Vaira D**, Gatta L, Ricci C, D'Anna L, Miglioli M.
 Helicobacter pylori: diseases, tests and treatment
 Digestive Liver Diseases 2001; 33: 788-94 (**I.F. 2.9**).
 129. Manes G, Balzano A, Iaquinto G, Ricci C, Piccirillo MM, Giardullo N, Todisco A, Lionello M,
Vaira D.
 Accuracy of the stool antigen test in post-eradication assessment of *Helicobacter pylori*
 infection.
 Digestive Disease Science 2001, 46: 2440-4. (**I.F. 1.5**).
 130. **Vaira D**, Gatta L, Ricci C, D'Anna L, Miglioli M
 How valuable is the application of Consensus guidelines in the management of functional
 gastrointestinal disorders
 Digestive Disease 2001, 19: 225-231 (**I.F. 1.5**)
 131. Spigelman M, Barnes I, Holton J, **Vaira D**, Thomas MG.
 Long-term DNA survival in ethanol-preserved archival material.
 Annals of Royal College of Surgeon 2001; 83: 283-4 (**I.F. 0.9**).
 132. Holton J, **Vaira D**.
 Gastric Helicobacters.
 Laboratory Diagnosis of Bacterial Infections, Edited by Nevio Cimolai 2001; 605-634.

2002

133. **Vaira D**, Vakil N, Menegatti M, van't Hoff B, Ricci C, Gatta L, Gasbarrini G, Quina M, Pajares J, van

- der Ende A, van der ulst R, Anti M, Duarte C, Gisbert J, Miglioli M, Tytgat G.
 The stool antigen H test for the detection of Helicobacter pylori after eradication therapy.
Annals of Internal Medicine 2002; 136: 280-87 (**I.F. 16.2**)
134. Vakil N, **Vaira D**. Bugs, drugs and dyspepsia in primary care. *BMJ USA* 2002; 2: 313-14. (**I.F. 13.7**).
 135. Perri F, Manes G, Neri M, **Vaira D**, Nardone G
Helicobacter pylori Antigen Stool Test and ¹³C Urea Breath Test in patients after eradication treatments
American Journal of Gastroenterology 2002; 97: 2756-62 (**I.F. 6**)
136. **Vaira D**, Holton J, Ricci C, Basset C, Gatta L, Perna F, Tampieri A, Miglioli M.
Helicobacter pylori infection from pathogenesis to treatment: a critical reappraisal
Alimentary Pharmacology & Therapeutics 2002; 16 (Suppl 4): 105-13 (**I.F. 4.3**).
 137. **Vaira D**, Gatta L, Ricci C, Miglioli M.
Diagnosis of Helicobacter pylori infection.
Alimentary Pharmacology & Therapeutics 2002; 16: 16-23 (**I.F. 4.3**).
 138. Palli D, Menegatti M, Masala G, Ricci C, Saieva C, Holton J, Gatta L, Miglioli M, **Vaira D**.
Helicobacter pylori infection, anti-cagA antibodies and peptic ulcer: a case-control study in Italy
Alimentary Pharmacology & Therapeutics 2002; 16:1015-20 (**I.F. 4.3**).
 139. Voland P, Weeks DL, **Vaira D**, Prinz C, Sachs G.
Specific identification of three low molecular weight membrane-associated antigens of Helicobacter pylori.
Alimentary Pharmacology & Therapeutics 2002; 16:533-44 (**I.F. 4.3**).
 140. Fernando N, Holton J, **Vaira D**, DeSilva M, Fernando D.
Prevalence of Helicobacter pylori in Sri Lanka as determined by PCR.
Journal of Clinical Microbiology 2002; 40:2675-6 (**I.F. 4.1**).
 141. Figura N, Piomboni P, Ponzetto A, Gambera L, Lenzi C, **Vaira D**, Peris C, Lotano MR, Giannace R, Nardi M, Bianciardi L, Renieri T, Valensin PE, Capitani S, Moretti E, Colapinto R, Baccetti B.
Helicobacter pylori infection and infertility.
European Journal of Gastroenterology & Hepatology 2002; 14:663-9 (**I.F.1.6**).
 142. Figura N, Palazzuoli A, Faglia S, Lenzi C, Borrello F, Palazzuoli V, Nami R, Dal Canto N, De Regis F, **Vaira D**, Giannace R, Gennari C.
The infection by CagA positive Helicobacter pylori strains is highly prevalent in patients with ischemic heart disease.
Digestive Diseases and Sciences 2002; 47: 831-36 (**I.F. 1.5**).
 143. Basset C, Holton J, **Vaira D**.
Helicobacter: a paradigm shift in peptic ulcer disease and more?
Science Progress 2002;85:13-31

2003

144. **Vaira D**, Vakil N, Rugge M, Gatta L, Ricci C, Menegatti M, Leandro G, Holton J, Russo V, Miglioli M
The effect of Helicobacter pylori eradication on development of dyspepsia and reflux disease in healthy asymptomatic subjects
Gut 2003; 52: 1543- 47 (**I.F. 9.3**)
145. Sapone A, **Vaira D**, S. Trepidi, Perna F, Gatta L, Tampieri A, Ricci C, Paolini M, Miglioli M, Biagi GL, Cantelli-Forte G
The clinical role of cytochrome P450 genotypes in Helicobacter pylori management.
American Journal of Gastroenterology 2003; 98: 1010-15 (**I.F. 6**)
146. Perna F, Gatta L, Figura N, Ricci C, Tampieri A, Holton J, Miglioli M, **Vaira D**
Metronidazole susceptibility for Helicobacter pylori
American Journal of Gastroenterology 2003; 98: 2157-61 (**I.F. 6**)
147. Gatta L, Perna F, Figura N, Ricci C, Holton J, D'Anna L, Miglioli M, **Vaira D**.
Esomeprazole versus omeprazole. Antimicrobial activity in vitro against Helicobacter pylori.

- Journal of Antimicrobial Chemotherapy 2003; 51:439-42 (**I.F. 4.3**)
148. Zullo A, **Vaira D**, Vakil N, Hassan C, Gatta L, Ricci C, De Francesco V, Menegatti M, Tampieri A, Perna, F, Rinaldi V, Perri, F, Papadia C, Fornari F, Pilati S, Mete LS, Merla A, Potì, R. Marinone G, Ravioli A, Campo SMA, Faleo D, Ierardi E, Miglioli, M, Morini S.
High eradication rates for *Helicobacter pylori* with a new sequential treatment
Alimentary Pharmacology & Therapeutics 2003; 17: 719-26 (**I.F. 4.3**).
149. Gatta L, Vakil N, Ricci C, Osborn J, Tampieri A, Perna F, Miglioli M, **Vaira D**.
A rapid, low dose ¹³C Urea tablet for the detection of Helicobacter pylori infection before and after treatment
Alimentary Pharmacology & Therapeutics 2003; 17: 793-798 (**I.F. 4.3**).
150. Bassett C, Holton J, Ricci C, Gatta L, Tampieri A, Perna F, Miglioli M, **Vaira D**.
Diagnosis and treatment of Helicobacter. A 2002 Updated review.
Alimentary Pharmacology & Therapeutics 2003; 17: 89-97 (**I.F. 4.3**).
151. Leodolter A, **Vaira D**, Bazzoli F, Schütze K, Hirschl A, Mégraud F, Malfertheiner P
European multicentre validation trial of two new non-invasive tests for the detection of H. pylori antibodies:
Urine-based ELISA and rapid urine test.
Alimentary Pharmacology & Therapeutics 2003; 18; 927-31 (**I.F. 4.3**).
152. Gatta L, Ricci C, Tampieri A, **Vaira D**.
Non invasive techniques for the diagnosis of Helicobacter pylori.
Clinical Microbiology & Infection 2003; 9: 498-96 (**I.F. 4**)
153. Gatta L, Ricci C, Stanghellini V, Ali' A, Menegatti M, Morselli Labate AM, Corinaldesi R, Miglioli M, **Vaira D**.
Best cut off values for 14C-urea breath tests for Helicobacter pylori detection.
Scandinavian Journal of Gastroenterology 2003; 38: 1144-8 (**I.F. 2**).
154. Dore MP, **Vaira D**.
Sheep rearing and Helicobacter pylori-implications for transmission of the infection (or sheep rearing and Helicobacter pylori infection- an epidemiological model of anthroponozoonosis.
Digestive Diseases and Sciences 2003; 35: 7-9 (**I.F. 1.5**).

2004

155. Nardone G, Rocco A, **Vaira D**, Staibano S, Budillon A, Tatangelo F, Scialli MG, Perna F, Salvatore G, Di Benedetto M, De Rosa G, Patrignani P.
Expression of COX-2, mPGE synthase 1, MDR-1 (P-GP) and BCL-XL: a molecular pathway of H pylori related-gastric carcinogenesis.
Journal of Pathology 2004; 202(3):305-12 (**I.F. 6.5**)
156. Gatta L, Vakil N, Ricci C, Osborn JF, Tampieri A, Perna F, Miglioli M, **Vaira D**.
Effect of Proton Pump Inhibitors and Antacid Therapy on ¹³C-Urea Breath Tests and Stool Test for *Helicobacter pylori* Infection
American Journal of Gastroenterology 2004; 99: 823-29 (**I.F. 6**)
157. Ricci C, Vakil N, M Rugge, Gatta L, Perna F, Osborn JF, Russo VM, Tampieri A, Miglioli M, **Vaira D**.
Serological markers for gastric atrophy in asymptomatic subjects infected with *Helicobacter pylori*.
American Journal of Gastroenterology 2004; 99: 1910-15 (**I.F. 6**)
158. Perna F, Figura N, Gatta L, Ricci C, Bernabucci V, **Vaira D**
Response to Dr Osato and Graham
American Journal of Gastroenterology 2004; 99: 2500 (**I.F. 6**)
159. C. Bassett, J. Holton, L. Gatta, C. Ricci, V. Bernabucci, G. Liuzzi, **D. Vaira**
Helicobacter pylori infection: anything new should we know?
Alimentary Pharmacology & Therapeutics 2004; 20: 1-10 (**I.F. 4.3**).
160. Gatta L, Perna F, Ricci C, Osborn JF, Tampieri A, Bernabucci V, Miglioli M, **Vaira D**
A rapid Immunochromatographic assay for *Helicobacter pylori* in stool before and after treatment
Alimentary Pharmacology & Therapeutics 2004; 20: 469-474 (**I.F. 4.3**).

161. Lahner E, **Vaira D**, Figura N, Pilozzi E, Pasquali A, Severi C, Perna F, Delle fave G, Annibale B.
Role of non-invasive tests (¹³C-urea Breath Test and Stool Antigen Test) as additional tool in diagnosis of Helicobacter pylori infection in patients with atrophic body gastritis
Helicobacter 2004; 4: 436-42 (I. F. 2.8)
162. **Vaira D**, Gatta L, Ricci C
Stool test for Helicobacter pylori
Digestive and Liver Disease 2004; 36: 446-7 (I.F. 2.9)
163. Zullo A, Hassan C, Morini S, De Francesco V, Ierardi E, Panella C, Gatta L, **Vaira D**
Sequential therapy for *H. pylori*: an “aberrant” therapy ready for general use.
Digestive and Liver Disease 2004; 36: 852-853(I.F. 2.5)
164. Basset C, Holton J, Bazeos A, **Vaira D**, Bloom S
Are Helicobacter species and Enterotoxigenic Bacteroides fragilis involved in Inflammatory Bowel? Disease
Digestive Disease and Sciences 2004; 49: 1425-32 (I.F. 1.5)
165. Vakil N, **Vaira D**
Non-Invasive tests for the diagnosis of Helicobacter pylori infection.
Diagnosis Updated 2004; X: 1-6.

2005

166. Gatta L, Zullo A, Perna F, Ricci C, De Francesco V, Tampieri A, Bernabucci V, Cavina, M, Hassan C, Ierardi E, Morini S, **Vaira D**.
A 10 days Levofloxacin base triple therapy in patients who failed two eradication courses
Alimentary Pharmacology & Therapeutics 2005; 22: 45-49 (I.F. 4.3).
167. Zullo A, Gatta L, De Francesco V, Hassan C, Ricci C, Bernabucci V, Cavina, M, Ierardi E, Morini S, **Vaira D**.
High Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study
Alimentary Pharmacology & Therapeutics 2005; 21: 1419-24 (I.F. 4.3).
168. O'Mahony R, Basset C, Holton H, **Vaira D**, Roitt I.
Comparison of image analysis software packages in the assessment of adhesion of micro organism of mucosal epithelium using confocal laser scanning microscopy.
Journal of Microbiological Methods 2005; 61:105-126 (I.F. 2.4)
169. O'Mahony R, Al-Khtheeri H, Weerasekera D, Fernando N, **Vaira D**, Holton J, Basset C.
Bactericidal and anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori.
World J Gastroenterol. 2005; 11(47):7499-507. (I: F: 2).
170. Manes G, Pieramico O, Perri F, **Vaira D**, Giardullo N, Romano M, Tardone G, Balzano A.
Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy.
Digestive Disease and Sciences 2005; 50: 443-48 (I.F. 1.5)
171. **Vaira D**, Gatta L, Ricci C, Tampieri A, Cavina, M, Bernabucci V, Miglioli M.
Peptic ulcer and Helicobacter pylori.
Postgraduate Medicine 2005; 17-22 (I: F: 0.8).
172. Salardi S, Cacciari E, Volta U, Santoni R, Ragni L, Elleri D, Cicognani A, **Vaira D**.
Growth and adult height in atypical celiac patients, with or without growth hormone deficiency.
Journal of Paediatric Endocrinology & Metabolism 2005; 18: 769-75 (I: F: 0.7).
173. O'Mahony R, **Vaira D**, Holton J, Basset C.
Helicobacter pylori: current status and future prospects.

2006

174. Gatta L, Ricci C, Tampieri A, Osborn J, Perna F, Bernabucci V, **Vaira D.**
Accuracy of breath tests using low doses of ^{13}C -urea to diagnose *Helicobacter pylori* infection:
A randomised controlled trial
Gut 2006; 55: 457-462 (**I.F. 9.3**).

2007

175. **Vaira D.**, Zullo A, Vakil N, Gatta L, Ricci C, Perna P, Hassan C, Bernabucci V, Tampieri A, Morini S.
Sequential therapy versus Triple Therapy for *Helicobacter pylori* Eradication: a randomized trial.
Annals of Internal Medicine 2007; 146: 556-563 (**I.F. 16.2**)
176. **Vaira D.**, Zullo A, Vakil N.
Sequential therapy: Minimizing risk and maximizing outcome.
Annals of Internal Medicine 2007; 147: 435-6. (**I.F. 16.2**)
177. Zullo A, De Francesco V, Hassan C, Morini S, **Vaira D.**
The sequential therapy regimen for *Helicobacter pylori* eradication.
Gut 2007; 56: 1353-57 (**I.F. 9.3**)
178. **Vaira D.**, Perna F.
How useful is the rapid urease test for evaluating the success of *Helicobacter pylori* eradication therapy?
Nature Clinical Practice Gastroenterology & Hepatology 2007; 4: 600-01 (**I.F. 4.5**).
179. Gatta L, **Vaira D.**, Sorrenti G, Zucchini A, Sama C, Vakil N.
Laryngeal symptoms and treatment for GERD. A systematic review and meta-analysis of the efficacy of proton pump inhibitors.
Alimentary Pharmacology & Therapeutics 2007; 25: 385-92. (**I.F. 4.3**).
180. Zullo A, Perna F, Hassan C, Ricci C, Saracino I, Morini S, **Vaira D.**
Primary antibiotic resistance in *Helicobacter pylori* strains isolated in Northern and Central Italy
Alimentary Pharmacology & Therapeutics 2007; 25: 1429-34. (**I.F. 4.3**).
181. Annibale B, Lahner E, Santucci A, **Vaira D.**, Pasquali A, Severi C, Mini R, Figura N, Delle Fave G.
CagA and VacA are immunoblot markers of past *Helicobacter pylori* infection in atrophic body gastritis.
Helicobacter 2007; 12: 23-30 (**I.F. 2.8**).
182. Ricci C, Holton J, **Vaira D.**
Diagnosis of *Helicobacter pylori*: invasive and non- invasive tests
Best Practice & Research Clinical Gastroenterology 2007; 21: 229-313 (**I.F. 2.5**)
183. Perna F, Zullo A, Ricci C, Hassan C, Morini S, **Vaira D.**
Levofloxacin-based triple therapy for *Helicobacter pylori* retreatment: role of bacterial resistance.
Digestive Liver Diseases 2007; 39:1001-5 (**I.F. 2.5**).
184. Zullo A, **Vaira D.**
Updated on the treatment of patients with *Helicobacter pylori*. (Letter).
American Family Physician 2007; 1; 76: 633. (**I.F. 1.7**).
185. **Vaira D.**, Ricci C, Lanzini A, Perna F, Romano A, Corinaldesi R.
How to proceed in H pylori-positive chronic gastritis refractory to first and second line eradication therapy.
Dig Dis. 2007;25:203-5 (**I.F. 1.5**).

2008

186. Vakil N, **Vaira D.**
Sequential therapy for *Helicobacter pylori*: Time to make the switch?
Journal of American Medical Association 2008; 300: 1346-7 (**I.F. 28.9**)

187. Gatta L, Zullo A, Di Mario F, **Vaira D.**
 Errors in a meta-analysis of treatment for *Helicobacter pylori* infection.
Annals of Internal Medicine 2008; 149: 686 (**I.F. 16.2**)
188. Vakil N, Zullo A, Ricci C, Hassan C, **Vaira D.**
 Duplicate breath testing to confirm eradication of *Helicobacter pylori*: incremental benefit and cost in 419 patients.
Alimentary Pharmacology & Therapeutics 2008; 28: 1304-8 (**I.F. 4.3**).
189. Romano M, Novene MR, Russo MI, Rocco A, Salerno R, Cozzolino D, Pilloni AP, Tufano MA, **Vaira D.**, Nardone G.
 Failure of first line eradication treatment significantly increases prevalence of anti-microbial resistant *helicobacter pylori* clinical isolates.
J Clin Pathol, 2008; 61: 1112-15 (**I.F. 2.4**).
190. Salardi S, Volta U, Zucchini S, Fiorini E, Maltoni G, **Vaira D.**, Cicognani A.
 The prevalence of celiac disease in children with type 1 diabetes mellitus increased in the mid nineties: an 18-yr longitudinal study based on anti-endomysial antibodies.
Journal of Paediatric Gastroenterology & Nutrition 2008; 46: 612-14. (**I.F. 2.1**).
191. Zullo A, Perna F, Ricci C, Hassan C, Tampieri A, De Francesco V, Morini S, **Vaira D.**
 13C-urea breath test values and *Helicobacter pylori* eradication.
Digestive Diseases and Sciences 2008; 53: 370-75 (**I.F. 1.5**).
192. **Vaira D.**, Figura N, Bernardini G, Braconi D, Santucci A.
 Diagnosis of *Helicobacter pylori* infection.
Medlab Magazine 3; 20-24.

2009

193. Gatta L, Vakil N, Leandro G, Di Mario F, **Vaira D.**
 Sequential therapy or triple therapy for *Helicobacter pylori*: systematic review and meta-analysis of randomized controlled trials in adult and children.
American Journal of Gastroenterology 2009; 104: 3069-79 (**I.F. 6**).
194. Zullo A, Hassan C, Andriani A, Cristofari F, De Francesco V, Ierardi E, Tomao S, Morini S, **Vaira D.**
 Eradication therapy for *Helicobacter pylori* in patients with gastric MALT-Lymphoma: a Pooled-data Analysis.
American Journal of Gastroenterology 2009, 104: 1932-7 (**I.F. 6**).
195. Younson J, O'Mahony R, Liu H, Grant S, Campion C, **Vaira D.**, Jennings L, Kelly CG, Roitt IM, Holton J.
 A human domain antibody and Lewis^b-glyconjugate that inhibit binding of *Helicobacter pylori* to Lewis^b receptor and inhibit bacterial adhesion to human gastric epithelium.
The Journal of Infectious Disease 2009; 200:1574-82 (**I.F. 5.8**).
196. De Francesco V, Zullo A, Ierardi E, **Vaira D.**
 Minimal inhibitory concentration (MIC) values and different point mutations in the 23S rRNA gene for Clarithromycin resistance in *Helicobacter pylori*.
Digestive and Liver Disease 2009; 41: 610-611 (**I.F. 2.9**).
197. De Francesco V, Zullo A, Ierardi E, Giorgio F, Perna F, Hassan C, Pannella C, **Vaira D.**
 The A2143G point mutation of Clarithromycin resistance affects H. pylori eradication.
Journal of Clinical Gastroenterology 2009; 43: 386 (**I.F. 2.2**).
198. **Vaira D.**, Gatta L, Ricci C, Di Mario F, Lanzini A.
 Accuracy of urea breath tests tablets after 10 minutes compared to standard 30 minutes to diagnose and monitoring *Helicobacter pylori* infection: a randomised controlled trial.
Journal of Clinical Gastroenterology 2009; 43: 693-94 (**I.F. 2.2**).
199. **Vaira D.**, Zullo A, Hassan C, Fiorini G, Vakil N.
 Sequential therapy for *Helicobacter pylori* eradication: the time is now!
Therapeutic Advances in Gastroenterology 2009; 2: 317-322.

2010

200. Gatta L, Di Mario F, **Vaira D.**
Treatment of Helicobacter pylori infection. .
Gut 2010; 59: 1300-1. (**I.F. 9.3) (letter)**)
201. Zullo A, De Francesco V, **Vaira D.**
Sequential therapy for H pylori eradication: is Levofloxacin better?
Gut 2010; in press (**I.F. 9.3) (letter)**)
202. Zullo A, Hassan C, Cristofari F, Andriani A, De Francesco V, Ierardi E, Tomao S, Stolte M, Morini S, **Vaira D.**
Effects of Helicobacter pylori eradication on early-stage gastric mucosa associated lymphoid tissue lymphoma.
Clin Gastroenterol Hepatol 2010; 8: 105-110. (**I.F. 5.6).**)
203. De Francesco V, Zullo Ierardi E, Giorgio F, Perna F, Hassan C, Morini S, Pannella C, **Vaira D.**
Phenotypic and genotype H. pylori Clarithromycin resistance and therapeutic outcomes: benefit and limits.
Journal of Antimicrobial Chemotherapy 2010; 65: 327–332 (**I.F. 4.3)**)
204. **Vaira D**, Vakil N, Gatta L, Ricci C, Perna F, Saracino I, Fiorini G, Holton J.
Accuracy of a new ultra fast rapid urease test to diagnose Helicobacter pylori infection in 1000 consecutive patients.
Aliment Pharmacology Ther 2010; 31: 331-338 (**I.F. 4.3).**)
205. Zullo A, Hassan C, D’Ercole C, De Francesco V, **Vaira D.**
Clarithromycin or Levofloxacin in the sequential therapy for H. pylori eradication?
Alimentary Pharmacology & Therapeutics 2010; 11:1249-50 (**I.F. 4.3) (Letter)**)
206. Perna F, **Vaira D.**
A new 24 hour Enzyme Immune Assay-culture based method for Helicobacter pylori Chemosusceptibility.
Journal of Clinical Pathology 2010; 63: 648-51 (**I.F. 2.3).**)
207. **Vaira D**, Gatta L, Ricci C, Perna F, Saracino I, Fiorini G, Castelli V, Holton J.
A comparison among three rapid urease tests to diagnose Helicobacter pylori infection in 375 consecutive dyspeptic.
Internal and Emergency Medicine 2010; 1: 41-47 (**I.F. 2.3).**)
208. Gatta L, Moayyedi P, Tosetti C, Vakil N, Ubaldi E, Barsanti P, Fiorini G, Castelli, Gargiulo C, Lucarini P, Lera M, Kaio E, Di Mario F, **Vaira D.**
A validation study of the Italian Short-Form Leeds Dyspepsia Questionnaire
Internal and Emergency Medicine 2010; 5: 501-506 (**I.F. 2.3).**)
209. Gatta L, Vakil N, **Vaira D**, Pilotto A, Curlo M, Comparato G, Leandro G, Ferro U, Lera M, Milletti S, Di Mario F.
Efficacy of 5-ASA in the treatment of colonic diverticular disease.
Journal of Clinical Gastroenterology 2010; 44:113-9 (**I.F. 2.2).**)
210. Fernando N, Torres P, **Vaira D**, Holton J.
Colonization by *Helicobacter pylori* of leprosy patients in Spain: immunomodulation to low molecular weight antigens of H pylori.
Memorias do Instituto Oswaldo Cruz 2010; 105: 682-6 (**I.F. 2.0)**)
211. De Francesco V, Zullo A, Perna F, Giorgio F, Hassan C, Vannella L, Cristofari F, Panella C, **Vaira D**, Ierardi E.
H. pylori antibiotic resistance and 13C urea breath test values.
J Med Microbiol. 2010; 59: 588-91 (**I.F. 1.45)**)

212. Caselli M, Holton J, Boldrini P, Vaira D, Calò G.
 Morphology of segmented filamentous bacteria and their patterns of contact with the follicle-associated epithelium of the mouse terminal ileum: implications for the relationship with the immune system
Gut Microbes
213. Gatta L, **Vaira D**, Fiorini G, Borghi C.
 Proton pump inhibitors and antiplatelet drugs in clinical cardiology.
Cardiology and Clinical Practice 2010, in press.
214. Abadi AT, Taghvaei T, **Vaira D**.
 Considerable use of furazolidone in Iran.
Saudi J Gastroenterol 2010; 16: 308-9. (letter)

2011

215. Gatta L, Di Mario F, **Vaira D**, Franzé A, Rugge M, Pilotto A, Lucarini P, Lera M, Scarpignato C.
 Diagnostic accuracy of serum pepsinogens and gastrin to follow-up
Helicobacter pylori infection: a pilot study .
Clin Gastroenterol Hepatol 2011; in press (**I.F. 5.6**).
216. Abadi ATB, Ajami A, Taghvaei T, Mobarez AM, Vaira D.
 Highly Correlation of *babA2*-Positive Strains of *Helicobacter pylori* In Presence of
 Gastric Cancer
Internal and Emergency Medicine 2011; in press (**I.F. 2.3**).
217. **Vaira D**, Gatta L, Ricci C, Castelli V, Fiorini G, Kaio E, Lanzini A.
 Gastroesophageal Reflux Disease and Barrett's Esophagus.
Internal and Emergency Medicine 2010; July (**I.F. 2.3**).
218. Gatta L, Di Mario F, **Vaira D**, Franzé A, Rugge M, Pilotto A, Lucarini P, Lera M, Fiorini G, Castelli V, Kaio E, Scarpignato C.
 Helicobacter pylori eradication: Are we really all equal? A controlled study
 in native and immigrant population.
Internal and Emergency Medicine 2011; 6: 35-39 (**I.F. 2.3**).
219. Gatta L, Di Mario F, Curlo M, **Vaira D**, Pilotto A, Lucarini P, Lera M, Enkleda K, Franzé A, Scarpignato C.
 Long-term treatment with mesalazina in patients with symptomatic uncomplicated diverticular disease.
Internal and Emergency Medicine 2010; in press (**I.F. 2.3**).

ARTICOLI SU RIVISTE NAZIONALI

2009

1. **Vaira D.**, Ricci C., Fiorini G., Lanzini A.
Helicobacter pylori: la nuova terapia.
Elisir di Salute 2009: Novembre-Dicembre pg. 35-37.
2. **Vaira D.**, Ricci C., Tosetti C.
La gestione di nausea e vomito in Medicina Generale.
M.D. Medicinae Doctor 2009; 6/7: pg. 18-20.
3. **Vaira D.**, Gatta L., Fiorini G., Castelli V. Di Mario F.
Infezione da Helicobacter pylori e nuovi orientamenti terapeutici: la terapia sequenziale.
M.D. Medicinae Doctor 2009; 33: pg. 20-22.
4. **Vaira D.**, Gatta L., Fiorini G., Borghi C.
La terapia gastroprotettiva nel paziente cardiopatico: un problema sempre attuale.
La Cardiologia nella Pratica Clinica 2009; 16: pg. 29-38.

2010


5. **Vaira D**, Gatta L, De Francesco V, Ricci C, Fiorini G, Castelli C, Ierardi E.
Nuovi orientamenti terapeutici per l’Infezione da *Helicobacter pylori*: La Terapia Sequentiale
Sequential therapy or triple therapy for *Helicobacter pylori* infection: systematic review and
Meta-analysis of randomized controlled trials in adults and children.
Italian Journal of Primary Care 2010; vol.2: pg. 120-124.
6. **Vaira D**, Gatta L, Fiorini G, Castelli C, Nasuto M, Di Mario F.
Nuovi orientamenti terapeutici per l’infarto da *Helicobacter pylori*: la terapia sequenziale.
Internal and Emergency Medicine 2010; volume 5, n1.
7. **Vaira D**, Fiorini G, Castelli C, Nasuto M, Ricci C.
Gestione del paziente, diagnostica rapida, nuove terapie per l’infarto da *Helicobacter pylori*.
Internal and Emergency Medicine 2010; volume 5, n1.
8. **Vaira D**, Gatta L, Ricci C, Di Mario F, Lanzini A.
Valutazione dell’accuratezza del nuovo urea breath test a lettura rapida nell’infarto da *Helicobacter pylori*.
Medical International Review 2010; 1-7.
9. **Vaira D**.
Nuovi orientamenti terapeutici per l’infarto da *Helicobacter pylori*: la terapia sequenziale.
Bollettino Notiziario dell’Ordine dei Medici Chirurghi degli Odontoiatri di Bologna 2010; 11; 9-15.
10. Gatta L, Gargiulo C, **Vaira D**.
Valutazione di economia sanitaria sull’infarto da *Helicobacter pylori*.
Avvenire Medico 2010 in corso di stampa.

ARTICOLI ON LINE SU SITI NAZIONALI

1. Medici Speciali Oggi, Springer on-line http://ecm.springer.com/speciali/03_09/index.php
2. M.D. Webtv. *Helicobacter pylori e rischio di carcinoma gastrico*.
<http://www.passioneditore.it/Vaira/>

Impact Factor pubblicazioni scientifiche Prof. Vaira 2010

(desunto dal Journal of Citation Reports,® ediz. 2008)



	IMPACT FACTOR DEL Prof. DINO VAIRO Science Citation Index 2008																													
	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	2000	01	02	03	04	05	06	07	08	09	10	Total
LANCET							20.8x1	20.8x1	20.8	20.8	20.8				20.8		20.8x2												338.8	
JAMA																												28.9		
Annals																												64.8		
Gastro.	12.9						12.9x1	12.9							12.9	12.9												77.4		
BMJ		12.7					12.7	12.7x1												12.7								69.5		
Gut			1.3x2				9.3x2	9.3	9.3	9.3	9.3				9.3x2	9.3		9.3		9.3	9.3		9.3	9.3		9.3x2	186			
GI End.				4.7																								6.7		
J Path																												19.5		
Am J G				6.0	6.0	6.0	6.0		6.0	6.0	6.0	6.0x2		6.0	6.0	6.0x2	6.0	6.0x2	6.0x2								6.0x2	138		
JID																												5.8		
Clinical																												5.6		
Endo.																												11		
Nu Cl P																												4.5		
JAC																												4.4		
AP&T																												13.2		
CO			4.3	4.3	4.3	4.3		4.3							4.3		4.3x2	4.3x2	4.3x4	4.3x2	103									
J Clin M																												25.8		
Br J So			4.1																									8.4		
Clin. Sci																												4.1		
CIMI																												4		
DLD	1.9	1.9				1.9	1.9x2								1.9	1.9x2	1.9	1.9	1.9	1.9	1.9x2		1.9	1.9			46.5			
Helic															2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8					16.8	
GCNA																												2.6		
BPRCG																												2.5		
JMM																												6.9		
IEM																												2.3x5		
JCP		2.3x2	2.3	2.3			2.3	2.3	2.3																	2.3				
JC Gas																												20.7		
JPGN																												2.2		
B&P			2.1																									4.4		
SGJ		2.1																										2.2		
MIOG																												4.2		
DDS							1.8							1.8	1.8x2	1.8x2	1.8x2	1.8x2	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1		
WJG																												2.1		
EJGH								1.7x2																			6.8			
Am FP																												1.7		
J P & T																												1.5		
DiDi							1.5																				6			
JMM																												1.5		
P MJ																												1.4		
CILab																												1.0		
JPEM																												14		
Tot	1.3	1.9	17	1	26	129	67	55	22	19	21	14.5	62	28	23	22	41	28	61	21	43.5	14	9	66	55	25	37.3	1279		

Legend

2008 Impact Factor

LANCET:	30.8
JAMA	28.9
Annals of Internal Medicine	16.2
B M J : British Medical Journal	13.7
Gastro. : Gastroenterology	12.9
GUT	9.3
GI End. : Gastrointestinal Endoscopy	6.7
A J G : American Journal of Gastroenterology	6.0
Endo. : Endoscopy	5.5
JID: Journal of Infectious Disease	5.9
Clinical Gastroenterology & Hepatology	5.6
J P & T: Alimentary Pharmacology & Therapy	4.3
CIMI I: Clinical Microbiology & Infection	4.0
BPRCG: Best Practice & Research Clinical Gastroenterology	2.5
JC Gastr: Journal of Clinical & Hepatology	2.2
JPP: Journal of Physiology and Pharmacology	1.5
DLD: Digestive Liver Disease	3.1
J Clin Gastro: Journal of Clinical Gastroenterology	2.2
Helicobacter	2.8
JCP : Journal of Clinical Pathology	2.3
IEM: Interna�o Emergency Medcine	2.4
J MM: Journal of Microbiological Method	2.3
JPGN:Journal Pediatric Gastroenterology & Nutrition	2.2
World J Gastroenterology	2.1
EJGH:European Journal Gastroenterology & Hepatology	1.7
B & P: Biomedicine and Pharmacotherapeutics	2.2
SGJ: Scandinavian Journal of Gastroenterology	2.1
DDS : Digestive Diseases and Sciences	1.8
DiDi: Digestive Disease	1.5
P MJ : Postgraduate Medical Journal	1.4
PM: Postgraduate Medicine	0.8
AGB: Acta Gastro-Enterologica Belga	0.8
JPEM: Journal of Paediatric Endocrinology & Metabolism	0.7
AnRCS: Annals of Royal College of Surgeon	0.9
C Th R: Current Therapeutic Research	0.23

		IMPACT FACTOR DEL Prof. DINO VAIRA Science Citation Index 2008																												
		82	83	84	85	86	88	89	90	91	92	93	94	95	96	97	98	99	2000	01	02	03	04	05	06	07	08	09	10	Totalc
Lancet							30.8x2	30.8x3	30.8	30.8	30.8	30.8	30.8	30.8	30.8	30.8x1											338.8			
JAMA																									28.9	28.9				
Annals																			16.2									64.8		
Gastro	12.9						12.9x2	12.9					12.9	12.9														77.4		
BMJ		13.7		13.7	13.7x2														13.7									68.5		
Gut		7.3x2					9.3	9.3	9.3	9.3	9.3	9.3	9.3	9.3	9.3	9.3	9.3	9.3	9.3	9.3	9.3	9.3	9.3	9.3x2	18.6					
GI End.			6.7																								6.7			
J Path																			4.5									19.5		
Am J G		6.0	6.0	6.0	6.0		6.0	6.0	6.0	6.0x1	6.0	6.0	6.0x3	6.0	6.0	6.0x1	6.0x3									6.0x1	13.8			
JID																										5.8	5.9			
CNCGH																										5.6	5.6			
Endo.			5.5																5.5								11			
Na Cl P																										4.5	4.5			
JAC																			4.4								4.4	13.2		
AP & T																			4.3								4.3x2	103		
CO																			4.3									25.8		
J Clin M																				4.2	4.2								8.4	
Br J Sur			4.1																									4.1		
Clin Sci																			4.1									4.1		
CIMicI																				4									4	
DLD	2.9	2.9					2.9	2.9x2					2.9	2.9x3	2.9	2.9	2.9	2.9	2.9x2		2.9	2.9						46.5		
Helic																		2.8	2.8	2.8	2.8	2.8	2.8				16.8			
GCNA																			2.6									2.6		
BPRCG																												2.5		
JMM																			2.3									6.9		
IEM																												2.3x5	7.2	
JCP		2.3x2	2.3	2.3			2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	20.7			
JGastr																												2.2	6.6	
JPGN																			2.2									4.4		
B&P			2.2																									2.2		
SJG		2.1																	2.1									4.2		
MIOC																												2	2.1	
DDS							1.8						1.8		1.8	1.8x2	1.8x2	1.8x2	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	27	
WJG																													2.1	
EJGH																			1.7x3										6.8	
Am FP																													1.7	
J P & T																			1.5										1.5	
DiDi																			1.5										6	
IMM																													1.5	
PMJ																			1.4										1.4	
Cl Lab																														1.0
Tot	13	19	17	1	98	189	67	55	52	19	31	15	63	30	53	92	41	38	61	51	43	16	9	66	55	25	57	1279		

Legend

2008 Impact Factor

LANCET:	30.8
JAMA	28.9
Annals of Internal Medicine	16.2
BMJ: British Medical Journal	13.7
Gastro.: Gastroenterology	12.9
GUT	9.3
GI End.: Gastrointestinal Endoscopy	6.7
AJ G : American Journal of Gastroenterology	6
Endo.: Endoscopy	5.5
JID: Journal of Infectious Disease	5.9
Clin Gastro Hepatol: Clinical Gastroenterology & Hepatology	5.6
J Path: Journal of Pathology	6.5
BJ S : British Journal of Surgery	4.1
NCPF&H:Nature Clinical Practice Gastroenterology& Hepatology	4.5
JAC: Journal of Antimicrobial & Chemotherapy	4.4
Clin Sci: Clinical Science	4.1
J Clin M : Journal of Clinical Microbiology	4.2
CO: Current Opinion in Gastroenterology	4.3
AP & Th: Alimentary Pharmacology & Therapy	4.3
CIMi I: Clinical Microbiology & Infection	4
DLD: Digestive Liver Disease	3.1
Helicobacter	2.8
BPRCG: Best Practice & Research Clinical Gastroenterology	2.5
IEM: Internal Emergency Medicine	2.4
J MM: Journal of Microbiological Method	2.3
JCP : Journal of Clinical Pathology	2.3
JGastr: Journal of Clinical & Hepatology	2.2
J Clin Gastro: Journal of Clinical Gastroenterology	2.2
JPGN:Journal Paediatric Gastroenterology & Nutrition	2.2
World J Gastroenterology	2.1
B&P: Biomedicine and Pharmacotherapeutics	2.2
SJG: Scandinavian Journal of Gastroenterology	2.1
DDS: Digestive Diseases and Sciences	1.8
EJGH:European Journal Gastroenterology & Hepatology	1.7
J PP: Journal of Physiology and Pharmacology	1.5
DiDi: Digestive Disease	1.5
PMJ : Postgraduate Medical Journal	1.4